Genetic control of the circulating concentration of transforming growth factor type β1

Human Molecular Genetics

Volumn 8, Issue 1, 1999, Pages 93-97

  Grainger, David J ^a   Heathcote, Kirsten ^a   Chiano, Mathias ^b,c   Snieder, Harold ^b   Kemp, Paul R ^a   Metcalfe, James C ^a   Carter, Nicholas D ^d   Spector, Tim D ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c Gemini Research Ltd   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DNA POLYMORPHISM; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC REGULATION; GENETIC VARIABILITY; HERITABILITY; HUMAN; NORMAL HUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE STRAND CONFORMATION POLYMORPHISM; TWINS;

ADULT; AGED; ALLELES; ARTERIOSCLEROSIS; BASE SEQUENCE; BONE DISEASES; DNA; DNA PRIMERS; FEMALE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MODELS, GENETIC; NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); TRANSFORMING GROWTH FACTOR BETA; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC; VARIATION (GENETICS);

EID: 0032958714     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/8.1.93     Document Type: Article

References (35)

1. Shirai, Y. et al (1992) Elevated levels of plasma TGF-β in patients with hepatocellular carcinoma. Jpn. J. Cancer Res., 83, 676-679.
2. -/- mice is prognostic for a high risk of malignant conversion. Cancer Res., 54, 5831-5836.
3. Ivanovic, V., Melman, A., Davis-Joseph, B., Valcic, M. and Geliebter, J. (1995) Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med., 1, 282-284.
4. Pierce, D.F., Gorska, A.E., Chytil, A., Meise, K.S., Page, D.L., Coffey, R.J. and Moses, H.L. (1995) Mammary tumour suppression by TGF-β1 transgene expression. Proc. Natl Acad. Sci. USA, 92, 4254-4258.
5. Markowitz, S. et al. (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science, 268, 1336-1338.
6. Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M. and Metcalfe, J.C. (1994) Activation of transforming growth factor β is inhibited in transgenic apolipoprotein(a) mice. Nature, 370, 460-462.
7. Grainger, D.J. et al. (1995) The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med., 1, 74-79.
8. Grainger, D.J., Witchell, C.M. and Metcalfe, J.C. (1995) Tamoxifen elevates TGF-β and suppresses diet-induced formations of lipid lesions in mouse aorta. Nature Med., 1, 1067-1072.
9. Anscher, M.S., Peters, W.P., Reisenbicher, H., Petros, W.P. and Jirtle, R.L. (1993) TGF-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Engl. J. Med., 328, 1592-1598.
10. Kulkarni, A.B. et al. (1995) Transforming growth factor-beta 1 null mice - an animal model for inflammatory disorders. Am. J. Pathol., 146, 264-275.
11. Danielpour, D., Kim, K.Y., Dart, L.L., Watanabe, S., Roberts, A.B. and Sporn, M.B. (1990) Evidence for differential regulation of TGF-β1 and TGF-β2 expression in vivo by sandwich enzyme-linked immunosorbent assays. Ann. NY Acad. Sci., 593, 300-302.
12. Grainger, D.J., Wakefield, L.M., Farndale, R., Bethell, H.W. and Metcalfe, J.C. (1995) Release and activation of platelet latent TGF-β in blood clots during dissolution with plasmin. Nature Med., 1, 932-937.
13. Grainger, D.J., Mosedale, D.E., Metcalfe, J.C., Weissberg, P.L. and Kemp, P.R. (1995) Active and acid-activatable TGF-β in human sera, platelets and plasma. Clin. Chim. Acta, 235, 11-31.
14. Kim, S.J., Glick, A., Sporn, M.B. and Roberts, A.B. (1989) Characterisation of the promoter region of the human transforming growth factor-β1 gene. J. Biol. Chem., 264, 402-408.
15. Kim, S.J., Wagner, S., Liu, F., O'Reilly, M.A., Dobbins, P.D. and Green, M.R. (1992) Retinoblastoma gene-product activates expression of the human TGF-β2 gene through transcription factor ATF-2. Nature, 358, 331-334.
16. Stunnenberg, H.G. (1993) Mechanisms of transactivation by retinoic acid receptors. Bioessays, 15, 309-315.
17. Danielpour, D. (1996) Induction of transforming growth factor β autocrine activity by all-trans retinoic acid and 1α-25-dihydroxy-vitamin D-3 in NRO-152 rat prostatic epithelial cells. J. Cell. Physiol., 166, 231-239.
18. Langdahl, B.L., Knudsen, J.Y., Jensen, H.K., Gregersen, N. and Erisksen, E.F. (1997) A sequence variation (713-8delC) in the TGF-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone, 20, 289-294.
19. Cambien, F., Ricard, S., Troesch, A., Mallet, C., Generenaz, L., Evans, A., Arveiler, D., Luc, G., Ruidavets, J.B. and Poirier, O. (1996) Polymorphisms of the TGF-β1 gene in relation to myocardial infarction and blood pressure - the ECTIM study. Hypertension, 28, 881-887.
20. Keen, R.W. et al (1998) A novel TGF-β1 gene polymorphism is linked and associated with hip BMD in female twins. J. Bone Mineral Res., (suppl.) (abstract).
21. Grainger, D.J. and Metcalfe, J.C. (1996) Tamoxifen - teaching an old drug new tricks? Nature Med., 2, 381-385.
22. Cui, W., Fowlis, D.J., Bryson, S., Duffie, E., Ireland, H., Balmain, A. and Akhurst, R.J. (1996) TGF-β1 inhibits the formation of benign skin tumours, but enhances the progression to invasive spindle carcinomas in transgenic mice. Cell. 86, 531-542.
23. Arteaga, C.L., Hurd, S.D., Winnier, A.R., Johnson, M.D., Fendly, B.M. and Forbes, J.T. (1993) Anti-TGF-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural-killer cell activity -implications for a possible role of tumour cell host TGF-β interactions in human breast cancer progression. J. Clin. Invest., 92, 2569-2576.
24. Torre-Amione, G., Beauchamp, R.D., Koeppen, H., Park, B.H., Schreiber, H., Moses, H.L. and Rowley, D.H. (1990) A highly immunogenic tumour transfected with murine TGF-β1 cDNA escapes immune surveillance. Proc. Natl Acad. Sci. USA, 87, 1486-1490.
25. Lawn, R.M., Pearle, A.D., Kunz, L.L., Rubin, E.M., Reckless, J., Metcalfe, J.C. and Grainger, D.J. (1996) Feedback mechanism of focal vascular lesion formation in transgenic apo(a) mice. J. Biol. Chem., 271, 31367-31371.
26. Reckless, J., Metcalfe, J.C. and Grainger, D.J. (1997) Tamoxifen decreases cholesterol seven-fold and abolishes lesion development in apoE knockout mice. Circulation, 95, 1542-1548.
27. MacAllister, K.A. et al (1994) Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet., 8, 345-349.
28. Grainger, D.J., Metcalfe, J.C., Grace, A.A. and Mosedale, D.E. (1998) TGF-β dynamically regulates vascular smooth muscle differentiation in vivo. J. Cell Sci., 111, 2977-2988.
29. Spector, T.D. et al. (1995) Influence of vitamin D receptor genotype on bone mineral density in post-menopausal women: a twin study in Britain. Br. Med. J., 310, 1357-1360.
30. Chiano, M.N. and Clayton, D.G. (1996) Haplotype analysis and the missing data problem. In Proceedings of the Genetic Analysis Workshop (GAW10), San Francisco, CA, October 26-28 (abstract).
31. Neale, M.C. (1995) Mx: Statistical Modelling. MCV, Richmond, VA.
32. Plomin, R., DeFries, J. and McClearn, G. (1989) Behaviour Genetics: A Primer, 3rd Edn. Freeman, San Francisco, CA.
33. Neale, M.C. and Cardon, L.R. (1992) Methodology for Genetic Studies of Twins and Families. Kluwer Academic Publishers, Dordrecht, The Netherlands.
34. Lange, K., Westlake, J. and Spence, M.A. (1976) Extensions to pedigree analysis: III. Variance components by the scoring method. Ann. Hum. Genet., 39, 485-491.
35. Zeger, S.L. and Liang, K.-Y. (1986) Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 42, 121-130.